EGFR-TKIs in combination with a therapy targeting the Src–YAP axis may overcome the resistance to EGFR-TKIs, and future clinical trials investigating this combination in EGFR-mutant NSCLC patients are warranted. The gene discussed is SRC; the disease is non-small cell lung carcinoma.